Avid Bioservices Inc (CDMO)

[cjgaddy]

Peregrine's Collab. with The NCCN models many others from 2014-2015...
http://www.nccn.org/clinical_trials/news.aspx

NCCN Awarded $2 Million in Research Funding from Peregrine Pharmaceuticals to Study Bavituximab in Various Cancers (01/06/2016)

NCCN Receives $2 Million in Research Funding from Boehringer Ingelheim to Study Targeted Combination Approaches with Afatinib in Lung Cancer (06/11/2015)

NCCN Receives $2-Million Funding Commitment from ImmunoGen to Study Mirvetuximab Soravtansine for Folate Receptor Alpha-Positive Cancers (05/15/2015)

NCCN Receives $2 Million in Research Funding from Boehringer Ingelheim to Study Volasertib in Hematologic Malignancies (05/22/2014)

NCCN Receives $2.2 Million in Research Funding from Astellas & Medivation to Study Enzalutamide in Solid Tumors (04/01/2014)

NCCN Receives $2 Million in Research Funding from Boehringer Ingelheim to Study Nintedanib* in Colorectal and Lung Cancers (03/21/2014)

= = = = = = = = =
1-6-16: Peregrine enters into Research Collab. with Natl-Comprehensive-Cancer-Network (NCCN) http://tinyurl.com/zmxtpsb
...$2mm res. grant to NCCN's Oncology Res. Pgm (ORP), will “significantly expand our clinical evaluation of Bavi and augment Peregrine's IST pgm at 26 of the world's leading cancer centers” [ http://www.nccn.org/members/network.aspx ].